Aramchol companion diagnostic - Galmed Pharmaceuticals/One Way Liver Genomics

Drug Profile

Aramchol companion diagnostic - Galmed Pharmaceuticals/One Way Liver Genomics

Latest Information Update: 07 Jul 2016

Price : $50

At a glance

  • Originator Galmed Pharmaceuticals; One Way Liver Genomics
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-alcoholic steatohepatitis

Most Recent Events

  • 30 Jun 2016 Galmed Pharmaceuticals signs an optional licensing agreement with Yeda Research and Development for commercialisation of the companion diagnostic tool
  • 23 Jul 2015 Galmed Pharmaceuticals and One Way Liver Genomics plan a phase III trial for Non-alcohollic steatohepatitis (Diagnosis) in USA and Europe ,
  • 08 Jul 2015 Galmed Pharmaceuticals enters into a research, option, license and a share purchase agreement with One Way Liver Genomics for development of a companion diagnostic tool
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top